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Abstract
Background: In a previous work we showed for the first time that human tumor cells secrete Hsp60 via exosomes, which are
considered immunologically active microvesicles involved in tumor progression. This finding raised questions concerning
the route followed by Hsp60 to reach the exosomes, its location in them, and whether Hsp60 can be secreted also via other
mechanisms, e.g., by the Golgi. We addressed these issues in the work presented here.
Principal Findings: We found that Hsp60 localizes in the tumor cell plasma membrane, is associated with lipid rafts, and
ends up in the exosomal membrane. We also found evidence that Hsp60 localizes in the Golgi apparatus and its secretion is
prevented by an inhibitor of this organelle.
Conclusions/Significance: We propose a multistage process for the translocation of Hsp60 from the inside to the outside of
the cell that includes a combination of protein traffic pathways and, ultimately, presence of the chaperonin in the circulating
blood. The new information presented should help in designing future strategies for research and for developing
diagnostic-monitoring means useful in clinical oncology.
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Introduction
Molecular chaperones, many of which are Heat shock proteins
(Hsps), are important players in protein homeostasis and cell and
tissue physiology, as well as in protection against stressors [1]. Hsps
intervene not only in protein folding, refolding, trafficking and
degradation but also in the regulation of cell growth and
differentiation, apoptosis and cell-to-cell crosstalk, inflammation,
and tissue repair [1,2].
The importance of chaperones has come into focus in the last
few years because it has been realized that they can be
pathogenetic factors in a variety of conditions named chaper-
onopathies [1]. Among these pathologies there are various forms
of cancer (chaperonopathies ‘‘by mistake’’ or ‘‘by collaboration-
ism’’), in which chaperones are normal but work in favor of the
tumor rather than protect the patient [3]. In these chaperono-
pathies by mistake, the chaperone involved enhances tumor cell
survival and growth by, for example, inhibiting apoptosis and the
anti-tumor immune response, or by promoting neoangiogenesis
[4–6].
That Hsp60 is actively involved in carcinogenesis has been
suspected for many years. Its levels have been found increased in
a number of neoplasms in which it may be found intra- and peri-
cellularly, and in circulation [for a review, see 7]. In a recent work,
we showed for the first time, that human tumor cells can secrete
Hsp60 via exosomes [8], extracellular vesicles with important roles
in immune system activation during cancer progression [9,10].
Exosomes are released from normal and tumor cells by multi-
vesicular bodies (MVB), a membranous intracellular complex
generated by the fusion of membrane-derived early endosomes
with other intracellular vesicles [9,10]. Lipid rafts and Golgi
vesicles participate in MVB formation [9,11]. The presence of
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Hsp60 in tumor derived exosomes raised questions such as: 1)
Does cytosolic Hsp60 reach the plasma membrane in tumor cells?
2) Are lipid rafts involved in Hsp60 membrane trafficking? 3)
What is the location of exosomal Hsp60? 4) Is it integrated in the
exosomal membrane? and 5) Is the Golgi involved in Hsp60
secretion from tumor cells, as well? The present work deals with
these questions. The results allowed us to outline the possible route
that Hsp60 follows inside tumor cells before its secretion into the
extracellular space, and provide clues for developing new
antitumor treatments centred on the chaperonin.
Results
Hsp60 is Present in the Tumor-cell Plasma Membrane
and in Lipid Rafts
Hsp60 was found in the plasma membrane fractions isolated
from H292 (human lung mucoepidermoid) and A549 (human lung
adenocarcinoma) cells (Fig. 1A). In contrast, Hsp60 was not
present in the plasma membrane fractions from the 16HBE line,
which derives from normal human bronchial epithelial cells (data
not shown). The levels of Hsp60 in the plasma membrane fractions
obtained from the tumor cells H292 and A549 were not the same
in all experiments, which could reflect different stages of the
chaperonin trafficking. The presence of Hsp60 in the plasma
membrane of the tumor cells was also demonstrated by Trans-
mission Electron Microscopy (TEM)-immunogold (Fig. 1B).
Hsp60 was localized not only in the plasma membrane but also
in the cytosol, very close to the plasma membrane, suggesting
active movement of the chaperonin in this area, possibly toward,
and also away from, the plasma membrane.
Since Hsp60 was present in the plasma membrane fraction
obtained from tumor cells, we performed experiments to de-
termine if the chaperonin occurred in the lipid rafts fraction
obtained from the same tumor cells. The results showed that
Hsp60 was present in the lipid rafts fractions obtained from H292
(Fig. 1C) and A549 (not shown) cells. The occurrence of Hsp60 in
the lipid rafts fractions of tumor cells is in agreement with our
previous data [8], showing that methyl-b-cyclodextrin (MBC),
a lipid-raft pathway inhibitor, reduced the quantity of Hsp60
released extracellularly from tumor cells. Altogether, the data
suggest that lipid rafts receive and then internalize Hsp60 from the
plasma membrane to intracellular vesicles, i.e., the microvesicular
bodies (MVB), thus participating in Hsp60 trafficking at the
plasma membrane level.
Hsp60 is Integrated in the Membrane of Exosomes
Derived from Tumor Cells
We have already demonstrated that Hsp60 occurs in exosomes
produced and released by tumor cells [8]. In this work, we
investigated if Hsp60 localizes in the exosomal membrane.
Clarification of this point is important because it is known that
proteins integrated in the exosomal membrane are putative ligands
for receptors present on the target cells, while proteins contained
inside exosomes are discharged into the cytosol of target cells
[9,10,12,13].
We performed experiments with exosomes purified from both
H292 (Fig. 2) and A549 (not shown) cells. We characterized the
purified exosomes by transmission electron microscopy (TEM)
(Fig. 2A) and by determining AChEase and ATPase enzymatic
activities (Fig. 2B and C), according to established criteria [9–12].
Subsequently, we looked for Hsp60 in the exosomal membrane.
As shown in Fig. 2D, Hsp60 was integrated in the exosomal
membrane. Our results do not exclude the presence of Hsp60 also
in the exosomal lumen.
Hsp60 Occurs also in the Golgi Apparatus
Since soluble free Hsp60 has been found in the circulating blood
of patients with some types of cancer [14], we investigated if this
chaperonin is secreted from H292 (Fig. 3) and A549 (not shown)
cells also via Golgi. We found Hsp60 inside the Golgi of tumor
cells by TEM-Immunogold (Fig. 3A). In addition, we performed
experiments using brefeldin A (BFA), a recognized selective Golgi
inhibitor, and we found that Hsp60 levels in the extracellular
medium of cultured tumor cells (conditioned medium) was
Figure 1. Hsp60 is present in the plasma membrane and lipid
rafts of tumor cells. A.Western blotting for Hsp60, and b1-integrin as
loading control, of isolated plasma membrane. Each lane represents
a separate experiment. Lanes 1–4, membrane from H292 tumor cells; 5–
8, membrane from A549 tumor cells. B. Transmission electron
microscopy-Immunogold demonstration of Hsp60 (black dots) in
H292 cells. Arrows indicate the Hsp60 molecules that are close or onto
the cell membrane. The inset shows the typical pattern of Hsp60 in
a mitochondrion, which serves as a positive internal control. Bar:
100 nm. C: Western blotting for Hsp60, caveolin-1, and b-tubulin in
isolated lipid rafts from H292 tumor cells. Hsp60 is present in lanes 2 to
6; caveolin-1 (marker for lipid rafts) is present in lanes 2 to 4; and b-
tubulin (cytosolic protein) is present in lanes 5 and 6.
doi:10.1371/journal.pone.0042008.g001
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significantly reduced by treating the cells with BFA, as shown by
Western blotting (Fig. 3B) and ELISA (Fig. 3C). In contrast, BFA
did not reduce the concentration of extracellular Hsp70 (Fig. 3B),
another well studied chaperone whose extracellular effects have
been documented [2].
Interestingly, we found a reduction of exosomal Hsp60 levels
after BFA treatment (Fig. 3D). While this finding was not
examined further, it may be taken to indicate that Golgi-derived
vesicles may usher Hsp60 toward MVB and then exosomes.
Discussion
Hsp60 levels are increased in a variety of tumors and pre-
neoplastic lesions in vivo, providing a potential means of diagnosis
and disease monitoring [reviewed in 7 and 15]. A role for Hsp60
in carcinogenesis has been postulated by various authors but it is
not yet fully understood [7,16–18]. Consequently, there is interest
in elucidating, for instance, the effects of Hsp60 (and also other
Hsps) on some types of cells such as those of the immune system
during carcinogenesis in vivo, particularly when the chaperones
gain the extracellular space and the circulation [15,19–21]. Since
the story must begin when the Hsp60 molecule exits the tumor
cell, we performed experiments to determine what secretion
mechanisms are involved at this early stage.
In previous work, we showed that Hsp60 is present in the
exosomes released from human tumor cells and that this release is
significantly reduced after treating the tumor cells with inhibitors
of the exosome and lipid-raft protein-trafficking pathways [8]. The
data opened new research avenues pertaining to the location of
Hsp60 in the tumor cell plasma membrane and lipid rafts, and in
the exosomes themselves. Furthermore, it was pertinent to ask the
question whether also the Golgi apparatus plays any role in the
Hsp60 movements inside the cell and toward the extracellular
space. All these are key aspects of Hsp60 physiology that require
elucidation in order to establish the chaperonin’s potential as
biomarker for diagnosis, disease monitoring and treatment, and to
design novel anti-cancer therapeutic strategies centred on the
chaperonin. Along these lines, in the present work we investigated
the presence of Hsp60 in the plasma membrane of tumor cells,
analogously to what has been done for other Hsps [22].
Membrane Hsps have been considered potentially convenient
targets for specific antibodies in therapeutic anti-tumor immunity
[23]. Our data provide evidence that Hsp60 could also be useful in
manipulating anti-tumor immunity with therapeutic purposes. In
this regard, it is particularly important to bear in mind that Hsp60
in normal cells is present mostly intracellularly with little presence
on the plasma membrane [24–27], which is in contrast with tumor
cells, at least in some types of tumors [28–30]. Therefore, in the
latter type of tumors, anti-Hsp60 antibodies would be expected to
hit tumor cells preferentially but much less their normal counter-
parts.
We found that Hsp60 is integrated in the exosome membrane.
This novel piece of information is important because it might
indicate that Hsp60 in the exosome membrane, like other proteins
in a similar location, would serve as a ligand for receptors on the
Figure 2. Hsp60 is integrated in the membrane of exosomes from tumor cells. A–C. Illustrative data on the exosome preparations utilized
in this work. A, Transmission electron microscopy demonstrates that the dimension of isolated vesicles is equal to, or smaller than 100 nm, which is
consistent with exosomes. Bar: 100 nm. B and C, acetylcholinesterase (AChEase) and ATPse enzymatic activities, respectively, typical of isolated
exosomal vesicles, compared to control (conditioned culture medium). In B, the solid line represents data from exosomes, and the broken line
represents results from conditioned culture medium. Vertical axis, AChEase activity in arbitrary units (AU), reflecting 412 nm absorbance; horizontal
axis, time of reaction in minutes. In C, 1, marker (positive control); 2, conditioned culture medium; 3, exosomes. D. Treatment with sodium carbonate
alone (lane 3, asterisk), or in association with proteinase K buffer (lane 4), does not remove Hsp60 from the exosomes, whereas treatment with
Proteinase K does (lane 2). Lane 1, untreated exosomes (positive control).
doi:10.1371/journal.pone.0042008.g002
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surface of cells targeted by the exosomes, such as cells of the
immune system, or tumor cells other than that from which any
given exosome originated. It is accepted that immune cells are
preferential targets for exosomes as these participate in immune
response regulation. Other exosome-bound Hsps, e.g., Hsp70,
have been found to recognize receptors on immune system cells
[21]. It has recently been reported that HepG2 cells (a human
hepatocellular carcinoma cell line) secrete Hsps, including Hsp60,
in exosomes [31]. The amount of secreted exosomal Hsp60
increased significantly after treating the HepG2 cells with
irinotecan hydrochloride and carboplatin, to which the cells were
resistant, in comparison with HepG2 cells stimulated with heat
shock or other drugs to which the HepG2 cells were not resistant.
The Hsp60-carrying exosomes derived from HepG2 cells treated
with the compounds to which they were resistant elicited a stronger
cellular immune anti-tumor response compared to exosomes from
HepG2 cells treated with other drugs, and this stronger response
was accompanied by granzyme B release and plasma-membrane
receptor density modification in NK cells. All together these data
support the view that Hsp-carrying exosomes from at least some
types of tumors and under certain conditions are stimulatory
vehicles than can elicit NK-cell bioactivity.
One may speculate that a way to modulate an anti-tumor
immune response would be to manipulate exosomes in what
Figure 3. Golgi involvement in Hsp60 secretion from tumor cells. A. TEM-Immunogold shows Hsp60 (black dots) in tumor cells, including in
the Golgi (framed by a dashed rectangle). The arrows show the plasma membrane and arrowheads indicate Hsp60 in it. Bar: 100 nm. B. Extracellular
levels of Hsp60 decrease after Brefeldin A (BFA) treatment of the tumor cells, as measured in immunoprecipitates from the conditioned medium (left
upper panel). In contrast, Hsp70 levels are not influenced by BFA treatment (left lower panel). Right hand panel: histograms showing densitometric
measurements of the Western blots to the left. UT, untreated; A.U.: arbitrary units; asterisk indicates p,0.005. C. ELISA results demonstrate
a reduction of Hsp60 levels in the conditioned culture medium from tumor cells after BFA treatment. UT: untreated.D. ELISA results show a reduction
of Hsp60 levels in exosomes after BFA treatment of the tumor cells. UT: untreated. Asterisks in C and D, p,0.05. Error bars represent SD.
doi:10.1371/journal.pone.0042008.g003
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regards their abundance in the circulation and Hsp60 cargo and
location by controlling, for example, lipid raft-mediated Hsp60
trafficking. The implications for clinical oncology are no doubt
potentially far reaching.
In this work, we also collected evidence in favour of
a participation of the Golgi in Hsp60 release from tumor cells.
Our data suggest that Hsp60, but not Hsp70, secretion from
tumor cells involves the Golgi apparatus, in addition to the
exosomal pathway as shown in a previous publication [8]. Our
data are in agreement with those of another group that recently
showed that Hsp60 was present in the Golgi apparatus of
malignant cells but not in the Golgi of normal cells and that
treatment with Brefeldin A influenced Hsp60 localization and
secretion by tumor cells [32]. In addition, our data suggest that the
Golgi apparatus could be responsible of Hsp60 import into
exosomal vesicles, as well as of Hsp60 secretion of the free, soluble
form detected in some tumor cases [14,33]. Unfortunately, little
attention has been given to the potential of Hsp60 as a biomarker
to be measured for assessing the clinical status of cancer patients
[14]. We hope our data will stimulate further research in this
direction.
In conclusion, this study sheds new light on the Odyssey of
Hsp60 inside the cell in which it originates, its exit from it, and its
voyage to its final destination in other cells. As a framework for
future research we propose a multistep process, outlined in Fig. 4.
This process would involve the plasma membrane, lipid rafts,
Golgi, MVB, and exosomes. We still need, for example, to
establish why and how cytosolic Hsp60 reaches the plasma
membrane, and whether post-translational modifications of the
chaperonin are involved. Another possibility that cannot be ruled
out at the present time is that Hsp60 does not travel alone but
bound together with another molecule (or molecules) and, thus,
translocates in ways and to places that would be impossible
otherwise. This thought is pertinent, for instance, in considering
the mechanism by which Hsp60 goes into the Golgi when it is
known that this chaperonin does not have a canonical Golgi-
localization signal. Finally, other points to be investigated are
whether extracellular Hsp60 is internalized by cells in the vicinity
of the cell that secretes it and, if so, whether this internalization
involves other molecules.
Methods
Cell Cultures
The human lung mucoepidermoid carcinoma H292, the
human lung adenocarcinoma A549 and the non-tumor human
bronchial epithelial 16HBE cell lines were obtained from the
American Type Culture Collection. H292 and A549 were
maintained in RPMI 1640 medium; 16HBE was maintained in
D-MEM medium. Both media were supplemented with 10% heat-
inactivated fetal calf serum and with 2 mM glutamine, 50 U/ml
penicillin, and 50 mg/streptomycin. Cells were grown as mono-
layers and cultured at 37uC, in an atmosphere with 5% CO2, in
a humidified incubator. Passage numbers of cells used in this study
ranged from 12 to 35. All cell culture reagents were purchased
from GIBCO BRL LIFE Technologies (Invitrogen, Milan, Italy).
All experiments were conducted at least in triplicate.
Transmission Electron Microscopy (TEM) Immunogold for
Hsp60
To detect human Hsp60, we used the following antibodies:
polyclonal rabbit anti-Hsp60 (clone H-300, Santa Cruz Bio-
technologies, Santa Cruz, CA, USA) diluted 1:15; and the goat-
anti rabbit IgG (H&L) 10-nm gold-conjugated Aurion (Ge
Healthcare, Milan, Italy), diluted 1:30.
After plating for 24 hours, H292 and A549 cells were fixed with
4% paraformaldehyde and 0.5% glutaraldehyde in 100 mM
sodium cacodylate buffer (pH 7.4) for 30 min and included the
same day. After fixation, samples were rinsed twice with 100 mM
sodium cacodylate buffer (pH 7.4), and then dehydrated with
ethanol (30%, 50%, 70%). After dehydration cells were embedded
into London Resin-white resin (L. R. White, London Resin Co,
London, U.K.) inside gelatin capsules at 60uC. The samples were
then cut into ultrathin sections. After pre-treatments with BSA for
10 min at 24uC, they were incubated with primary anti-Hsp60
antibody for 1 hour. Following washing in PBS (5 times for 5 min
each) the sections were incubated with secondary anti-rabbit
antibody for 1 hour. Sections were then washed in PBS and then
with distilled water, and were stained with uranyl acetate and
subsequently examined by JEOL JEM 1220 TEM at 120 kV.
Isolation of Plasma Membranes and Lipid Rafts
We used, with some modifications, the technique described by
Barbieri et al. [34] for plasma membranes isolation from H292,
A549, and 16HBE cells and the method published by Xavier et al.
[35] for lipid rafts isolation from H292 and A549 cells.
To isolate plasma membrane, the cells were first swollen in
hypotonic buffer (5 mM KC1, 1 mM Mg C12, 20 mM Hepes
pH 7.9, and 1 mM Na3VO4) containing an anti-proteases cocktail
for 30 min on ice, then lysed with a tight-fitting pestle of a potter
homogenizer (60 strokes). Nuclei were separated by centrifugation
at 10006g for 10 min at 4uC. The supernatant was centrifuged at
100,0006g for 30 min at 4uC to pellet the plasma membrane
fractions and yield the cytosolic fractions. The plasma membrane
fractions were extracted in buffer A (25 mM Tris, pH 7.5,
250 mM sucrose, 2.5 mM MgC12, 5 mM EGTA, 5 mM EDTA,
1% Triton X-100, 0.5% deoxycholate, 1 mM Na3VO4 and
protease inhibitors) for 30 min on ice, centrifuged at 10,0006g for
30 min at 4uC to pellet debris.
To isolate the lipid raft fractions, cells were lysed in MBS buffer
(25 mM MES, 2 mM EDTA pH 8, and 150 mM NaCl) contain-
ing 1% Triton X 100 and anti-proteases cocktail for 30 min on ice.
The lysates, mixed with an equal volume of 85% sucrose (w/v) in
MBS buffer, were placed at the bottom of a polycarbonate
ultracentrifuge tube (Beckman Instruments, Palo Alto, CA, USA),
overlaid with 2 ml of 35% sucrose and 1 ml of 5% sucrose in MBS
buffer containing 2 mM EDTA pH 8 and anti-proteases cocktail
and were centrifuged at 100,0006g for 20 hours at 4uC in a SW55
Ti rotor (Beckman Instruments). Six fractions of 550 ml/each were
collected from the top of the discontinuous sucrose gradient. The
isolated plasma membrane fractions and lipid rafts were used
directly in SDS-PAGE and Western blotting, as described below.
Protein Quantification
Proteins from plasma membrane and lipid rafts preparations
were quantified with the Quant-iT TM protein assay kit, using
Qubit fluorometer (Invitrogen Molecular Probes, Invitrogen,
Milan, Italy), according to the manufacturer’s instructions. The
kit is accurate for protein concentrations raging from 12.5 mg/ml
to 5 mg/ml.
Western Blotting
We used the following primary antibodies: anti-Hsp60 mono-
clonal antibody (clone LK1, Sigma-Aldrich Inc, Milan, Italy),
diluted 1:1,000; anti-Hsp70 monoclonal antibody (clone W27,
Santa Cruz Biotechnologies), diluted 1:1,000; anti-b1-integrin
monoclonal (clone N29, Chemicon- Millipore Corporation, Bill-
Hsp60 Voyages and Locations in Cancer
PLoS ONE | www.plosone.org 5 July 2012 | Volume 7 | Issue 7 | e42008
erica, MA, USA) diluted 1:1,000; anti-caveolin-1 monoclonal
antibody (clone 4H312, Santa Cruz Biotechnologies), diluted
1:1,000; anti-b-tubulin monoclonal antibody (clone TUB 2.1,
Sigma-Aldrich Inc), diluted 1:1,000. Western blotting was
performed as previously described [8]: briefly, 40 ml of samples
was added to 4x Laemmli buffer and heated for 5 min at 95uC.
Proteins were resolved by 12% SDS PAGE along with molecular
weight marker (Bio-RAD Laboratories, Milan, Italy). Proteins
were then transferred to nitrocellulose membranes. The mem-
branes were blocked with 5% fat milk, and probed for 12 hours
with the primary antibodies, followed by incubation with
horseradish peroxidase-conjugated second antibody (Amersham
Biosciences, Milan, Italy) diluted 1:5,000. Blots were detected
using Supersignal West Femto, according to the manufacturer’s
instructions (Pierce, Milan, Italy) and chemiluminescent signals
were recorded with ChemiDoc XRS imager (Bio-RAD Labora-
tories). Densitometric analysis of plots was performed using the
NIH Image J analysis program (National Institutes of Health,
Bethesda, MD, USA). Western blotting for Hsp60 and anti-b1-
integrin detection in plasma membrane was performed loading
100 mg of proteins in each lane. Western blotting for Hsp60,
caveolin-1, and b-tubulin detection in lipid rafts was performed
loading 50 mg of proteins in each lane.
Isolation of Exosomal Fractions
1. Conditioned medium: Eighty ml of conditioned medium from
70–806106 cells (H292 or A549) were collected after 24 hours
of culture in serum-free medium, and centrifuged (8006g for
10 min) at 4uC to eliminate cells and debris.
2. Purification of exosomes: Exosomes were isolated as previously
described [8]: briefly, 50 ml of cell- and debris-free medium
was collected on ice and centrifuged at 13,0006g for 20 min at
4uC to bring down and eliminate small cellular debris and
Figure 4. Proposed Hsp60 secretion pathways in a tumor cell. Hsp60 (black dots) that in normal cells localizes mainly in mitochondria, in
tumor cells accumulates also in the cytoplasm and, for unknown reasons (post-translational modifications?), reaches the cell membrane and the
Golgi. At the membrane, lipid rafts internalize (endocytose) Hsp60 toward multivesicular bodies (MVB) from where it is secreted via exosomes. In
these, it is located in the membrane and probably also inside. Hsp60-loaded exosomes thus would reach other cells near and far through the
circulation. The Golgi may also participate in Hsp60 secretion via transport vesicles moving to both MVB and the extracellular space. Hsp60 released
in the extracellular space by Golgi vesicles (free Hsp60) can thus reach other cells in the vicinity and distant via circulation.
doi:10.1371/journal.pone.0042008.g004
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mitochondrial contaminants. The supernatant was collected
and exosomes were separated from it by centrifugation at
110,0006g for 2 hours at 4uC in a Beckman 60 Ti rotor; the
pellet (called ‘‘exosomal fraction’’) was collected and washed
once in phosphate-buffered saline (PBS), resuspended in 100 ml
of PBS containing proteases inhibitor, and stored at 280uC
until use.
3. Assessment of exosomes’s quality by transmission electron
microscopy (TEM): Exosome pellets purified from the cell lines
studied were first examined by TEM to ascertain the presence
of exosomal vesicles, whose diameter has to be 100 nm or less
[9,10]. Pellets were resuspended in residual fluid from PBS
wash, followed by addition of 100 ml freshly made fixative
(2.5% glutaraldeyde in PBS) to preserve vesicle structure and
morphology. Preparations were mounted on formvar nickel
300-mesh grids by layering grids over 10 ml drops of exosome
preparations for 10 min at 24uC. Grid-mounted preparations
were stained with uranyl acetate and lead citrate, and
subsequently examined with JEOL JEM 1220 TEM at 120 kV.
4. Assessment of exosomes’s quality by acetylcholine esterase
(AChEase) and ATPase assays: We measured the activity of
AChEase and ATPase, two enzymes that are considered
reliable markers for these vesicles [9,10]. AChEase assay was
performed as previously described [8]: briefly, 15 ml of the
exosomal preparation was suspended in 100 ml of PBS and
incubated with acetylcholine (1.25 mM) and 5,59–dithio-bis-(2-
nitrobenzoic) acid (0.1 mM) in a final volume of 1 ml. The
incubation was carried out in cuvettes at 37uC and the change
in absorbance at 412 nm was monitored every 5 min for
30 min by a plate reader (Titertek Multiscan MCC/340, Flow
Laboratories, Lugano, Switzerland). ATPase assay was per-
formed as previously described [36]: briefly, the exosome
fraction was added to ATPase buffer (6.6 mM HEPES
(pH 7.6), 0.66 mM EDTA, 0.66 mM 2-mercaptoethanol,
0.033% NP-40, 1.1 mM MgCl2, 33 mM ATP, 5 mCi (c-33P)
ATP-3000 mmol21 (Ge Healthcare)), and 100 ng of plasmidic
DNA was used as substrate. The cell culture medium was used
as control and it was setup in parallel. The reactions were
incubated for 30 minutes at 24uC. Unreacted ATP and free y-
phosphate were separated by thin layer chromatography using
TLC cellulose (Merck Millipore, Milan, Italy). ATP hydrolysis
quantification was detected with a Bio-RAD, Personal
Molecular Imager FX System.
Search for Hsp60 Presence in the Exosomal Membrane
With the aim to determine whether the Hsp60 was embedded in
the exosomal membrane, we used H292 and A549 cells and
applied, with some modifications, the techniques described by
Fujiki et al. [37] for sodium carbonate treatment of isolated
membranes, and the method by Hardy et al. [38] for proteolysis of
extracellular membranes by proteinase K treatment. The sodium
carbonate treatment flattens the exosomal membrane and releases
proteins that are not integrated into the membrane [37], while the
proteinase K treatment disrupts the exosomal membrane, re-
leasing all proteins contained in it [38]. Briefly, sodium carbonate
treatments were performed treating exosomes with 1 M Na2CO3,
pH 11.5, for 30 min at 37uC. Proteinase K treatments was
performed resuspending a pool of carbonate-treated exosomes in
7 mM proteinase K plus a buffer made of 10 mM EDTA and
5 mM N-ethylmaleimide (NEM). Finally, another pool of carbon-
ate-treated exosomes was resuspended only in proteinase K buffer
(10 mM EDTA plus 5 mM NEM); this treatment does not modify
the results of carbonate-treatment alone and was made as internal
control. After treatments, the exosomes were collected by high
speed centrifugation for 2 hours at 4uC in a Beckman rotor Ti50.
The exosomes fractions obtained were used for Western blotting.
Treatments with Golgi Inhibitor
We reproduced, with some modifications, the technique de-
scribed by Hardy et al. [38] for Brefeldin A (BFA) treatments,
using H292 and A549 cells. Briefly, cells were seeded in serum-free
medium under the same conditions described earlier and treated
with 1 mg/ml of BFA for 30 min, followed by a 4-hour recovery
period. Extracellular medium was used for immunoprecipitation
or for purification of exosomes, as described before.
Immunoprecipitation
Immunoprecipitation of proteins obtained from extracellular
conditioned medium was performed as previously described [8]:
briefly, to assess the presence and quantity of Hsp60 in the
conditioned medium after BFA treatments, 500 mg of proteins
were incubated with 3 mg of anti-Hsp60 monoclonal antibody
(clone LK1, Sigma-Aldrich Inc.) at 4uC for 2 hours, followed by
incubation with 20 ml protein-A Sepharose at 4uC for 12 hours.
Subsequently, the incubation mixture was centrifuged in a micro-
centrifuge at 14,0006g for 30 seconds at 4uC, the pellet was
collected and resuspended in 16lysis buffer (20 mM Tris-HCl
(pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1%
Triton, 2.5 mM sodium pyrophosphate, 1 mM b-glyceropho-
sphate, 1 mM Na3VO4, 1 mg/ml leupeptin) and centrifuged
again. This procedure was repeated three times. The last pellet
was solubilised by boiling into 26sample buffer (2% SDS, 10%
glycerol, 100 mM DTT, 60 mM Tris-HCl (pH 6.8) and 0.001%
bromophenol blue), and used for SDS-PAGE as described (see
‘‘Western blotting’’ Section, above). The same protocol, using anti-
Hsp70 monoclonal antibody (clone W27, Santa Cruz Biotechnol-
ogies), was applied to assess Hsp70 levels.
ELISA
ELISA tests were performed as previously described [8]: briefly,
quantitative comparisons of Hsp60 levels in conditioned media
and exosomes from H292 and A549 cells were performed using
a commercial Hsp60 EIA Kit from Stressgen Assay Designs Inc.
(Ann Arbor, MI, USA). The results obtained with this assay were
normalized for cell number and expressed as pg/mL/106 cells.
Statistical Analysis
Data are presented as the mean 6 SD of triplicate determina-
tions. Comparisons between groups were performed using the
unpaired samples Student’s t test. A p value ,0.05 was considered
statistically significant.
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